VistaGen Therapeutics, Inc. , a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving ... (more)
http://www.biospace.com/news_story.aspx?StoryID=285501&full=1
http://www.biospace.com/news_story.aspx?StoryID=285501&full=1
No comments:
Post a Comment